Anti-angiogenic Ophthalmic Agents Market Size by Indication Type, Distribution Channel, Region, Industry-Wide Analysis, Competitive Landscape Assessment & Long-Term Forecast to 2032
Overview
The Anti-angiogenic Ophthalmic Agents Market size was valued at USD 4.24 Billion in 2025 and the total Anti-angiogenic Ophthalmic Agents revenue is expected to grow at a CAGR of 3.89% from 2025 to 2032, reaching nearly USD 5.53 Billion by 2032.
Anti-angiogenic Ophthalmic Agents Market: Overview
The Anti-angiogenic ophthalmic agents act as antagonists against the vascular endothelial growth factor (VEGF). When retinal pigment cells become ischemic and dry up VEGF stimulates generation of new blood vessels by a process called neovascularization. If new blood vessels are not generated properly, leakage occurs in retina, which leads to vision loss. Angiogenesis plays an important role in chronic inflammation and fibrosis, tumor growth and vascularization of ischemic tissue.
To Know About The Research Methodology :- Request Free Sample Report
Anti-angiogenic Ophthalmic Agents Market: Dynamics
Increasing prevalence of Ocular diseases is the key driving factor for the market growth.
Diabetic retinopathy remains one of the greatest challenges for healthcare system worldwide despite the fact that the incidence of visual acuity impairment in diabetic population has decreased due to examination quality improvement and dynamic observation of patients. According to the World Health Organization, a significant increase worldwide in number of patients with Diabetes Mellitus, is expected to reach 629 million by the year 2045. Along with this, rising prevalence of age-related macular degeneration (AMD), which is the leading cause of severe vision loss among geriatric population in many western countries is also bolstering the market growth. Many treatment options are available to treat the ocular diseases. The Laser Coagulation of the Retina (LCR) is used to treat diabetic retinal lesions. However, despite the proven efficacy of LCR some patients continue to lose their vision despite treatment. This may be due to both the complications of laser treatment (development of serpiginous atrophy and subretinal fibrosis) and resistance to its effects. This factor may restrain the market growth.
The report has profiled twenty key players in the market from different regions. However, the report has considered all market leaders, followers, and new entrants with investors while analyzing the market and estimation the size of the same. Increasing R&D activities in each region are different and focus is given on the regional impact on the cost, availability of advanced technology are analyzed and the report has come up with recommendations for a future hot spot in the APAC region.
Segment Analysis
By Indication Type, Macular Edema segment is expected to dominate the market.
Macular edema is the build-up of fluid in the macula, an area in the center of the retina. The retina is the light-sensitive tissue at the back of the eye and the macula is the part of the retina responsible for sharp, straight-ahead vision. Fluid buildup causes the macula to swell and thicken, which distorts vision. The current standard of care for macular edema is intravitreal injection or anti-VEGF injection. A recent NEI-supported clinical trial that directly compared the effectiveness of the three drugs for DME found that the drugs performed similarly for patients with mild vision problems. However, Eylea performed better for those with more serious vision loss. The global prevalence of Diabetic Macular Edema (DME) among individuals with Type 1 Diabetes Mellitus or Type 2 Diabetes Mellitus varies by geographic region, with rates as low as 11.4% in European countries to as high as 45.3% in North American countries.
Regional Insights
North America accounted for largest market share in the year 2025, followed by Europe.
Increasing prevalence of eye related disorders like AMD, cataract, glaucoma, diabetic retinopathy, diabetic macular edema and dry eye disorders in the region and high availability of commercialized Anti-angiogenic Ophthalmic Agents are some of the driving factors for market in the region. Age-related macular degeneration (AMD) complications are the leading cause of severe vision loss among people aged 65 years and over in the United States and many western countries. For instance, in 2021, Bausch + Lomb launched Ocuvite Eye Performance vitamin supplements in the U.S. in order to meet the increasing needs of U.S. consumers. Besides this, Europe held the second largest share owing to increasing prevalence of myopic choroidal neovascularization in the region.
Asia Pacific is expected to witness fastest growth.
Increasing prevalence of diabetes and other eye related disorders in Asian countries with rising geriatric population pool who are more susceptible in acquiring these vision impairments will contribute to the market growth.
The report also helps in understanding Global Anti-angiogenic Ophthalmic Agents Market dynamics, structure by analyzing the market segments and project the Global Anti-angiogenic Ophthalmic Agents Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global Anti-angiogenic Ophthalmic Agents Market make the report investor’s guide.
Anti-angiogenic Ophthalmic Agents Market Scope: Inquire before buying
| Anti-angiogenic Ophthalmic Agents Market | |||
|---|---|---|---|
| Report Coverage | Details | ||
| Base Year: | 2025 | Forecast Period: | 2026-2032 |
| Historical Data: | 2020 to 2025 | Market Size in 2025: | USD 3.20 Bn. |
| Forecast Period 2026 to 2032 CAGR: | 3.89% | Market Size in 2032: | USD 4.49 Bn. |
| Segments Covered: | by Indication Type | Myopic Choroidal Neovascularization Macular Edema Diabetic Retinopathy Macular Degeneration |
|
| by Distribution Channel | Retail Pharmacies Online pharmacies Hospital pharmacies |
||
Anti-angiogenic Ophthalmic Agents Market, by Region
North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)
Anti-angiogenic Ophthalmic Agents Market Key Players
1. Gilead Sciences, Inc.
2. Eyetech Inc.
3. Becton, Dickinson and Company
4. Regeneron Pharmaceuticals, Inc.
5. Genentech, Inc.
6. Novartis AG
7. Allergan plc
8. Bayer AG
9. Santen Pharmaceutical Co., Ltd.
10.Shanghai Pharmaceuticals
11.Johnson & Johnson
12.Pfizer
13.Sun Pharma
14.Otsuka Pharmaceutical Co. Ltd
15.Daiichi Sankyo
16.ERC Labs
17.Medicom Health care
18.Implandata ophthalmic products GmbH
19.The Geuder Group, MORCHER GmbH
20.Novamedika
Frequently Asked Questions:
1. Which region has the largest share in Global Anti-angiogenic Ophthalmic Agents Market?
Ans: North America region held the highest share in 2025.
2. What is the growth rate of Global Anti-angiogenic Ophthalmic Agents Market?
Ans: The Global Anti-angiogenic Ophthalmic Agents Market is growing at a CAGR of 3.89% during forecasting period 2026-2032.
3. What is scope of the Global Anti-angiogenic Ophthalmic Agents Market report?
Ans: Global Anti-angiogenic Ophthalmic Agents Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period.
4. Who are the key players in Global Market?
Ans: The important key players in the Global Market are – Gilead Sciences, Inc., Eyetech Inc., Becton, Dickinson and Company, Regeneron Pharmaceuticals, Inc., Genentech, Inc., Novartis AG, Allergan plc, Bayer AG, Santen Pharmaceutical Co., Ltd., Shanghai Pharmaceuticals, Johnson & Johnson, Pfizer, Sun Pharma, Otsuka Pharmaceutical Co. Ltd, Daiichi Sankyo, ERC Labs, and Medicom Health care.
5. What is the study period of this Market?
Ans: The Global Anti-angiogenic Ophthalmic Agents Market is studied from 2025 to 2032.